Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
---|---|---|---|---|
Grassi C et al. | 2004 | intact cell/cell culture, human neuroblastoma cell line (IMR 32) and rat pituitary (GH3) cell line | magnetic field, low frequency, 50/60 Hz, co-exposure | 200–500 µT |
Duong CN et al. | 2016 | intact cell/cell culture, HMO6 cells (human microglial cell line) | magnetic field, low frequency, 50/60 Hz, co-exposure | 0.01–1 mT |
Hosseinabadi MB et al. | 2019 | human | magnetic field, low frequency, 50/60 Hz, occupational | 11.3–18.9 µT |
Cecconi S et al. | 2000 | intact cell/cell culture, ovarian follicles from mice (Swiss CD1) | magnetic field, low frequency, signals/pulses, 50/60 Hz | 1.5 mT |
Crocetti S et al. | 2013 | intact cell/cell culture, MCF-7 cells (human breast cancer cell line) and MCF-10 cells (human non-tumorigenic breast epithelial cell line) and C2C12 cells (mouse myoblast cell line) | magnetic field, low frequency, signals/pulses, 50/60 Hz | 2–5 mT |
Akbarnejad Z et al. | 2017 | intact cell/cell culture, U87 (human glioblastoma cell line) | magnetic field, signals/pulses, 50/60 Hz | 5–10 mT |
Oladnabi M et al. | 2019 | - | magnetic field, signals/pulses, 50/60 Hz | - |
Kaszuba-Zwoinska J et al. | 2010 | intact cell/cell culture, U937 (human leukemic monocyte cell line) | magnetic field, signals/pulses, 50/60 Hz, co-exposure | 45 mT |
Kaszuba-Zwoinska J et al. | 2012 | intact cell/cell culture, Mono Mac 6 cells (human monocytes) | magnetic field, signals/pulses, 50/60 Hz, co-exposure | 45 mT |
Mercado-Sáenz S et al. | 2023 | intact cell/cell culture, yeast (<i>Saccharomyces cerevisiae</i>)/WS8105-1C | magnetic field, signals/pulses, 50/60 Hz, co-exposure, also other exposures without EMF | - |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.